{"id":7073310,"date":"2026-10-02T20:13:21","date_gmt":"2026-10-02T20:13:21","guid":{"rendered":"https:\/\/fivemor.com\/?p=7073310"},"modified":"2026-10-02T20:13:21","modified_gmt":"2026-10-02T20:13:21","slug":"pfizer-pills-phase-3-data-in-vitiligo-pave-way-for-fda-ema-submissions","status":"publish","type":"post","link":"https:\/\/fivemor.com\/?p=7073310","title":{"rendered":"Pfizer Pill\u2019s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<p><a href=\"https:\/\/medcitynews.com\/2026\/10\/pfizer-vitiligo-litfulo-ritlecitinib-jak-tec-inhibitor-autoimmune-disease-immunology-pfe\/\"><img loading=\"lazy\" decoding=\"async\" width=\"724\" height=\"483\" src=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/10\/vitiligo_hands.jpg\" class=\"attachment-large size-large wp-post-image\" alt=\"\" style=\"max-width: 100%;height: auto!important\" \/><\/a><\/p>\n<p>Pfizer\u2019s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during European Academy of Dermatology and Venereology annual meeting. If Pfizer\u2019s daily pill is approved, it would compete against an Incyte topical cream that is currently the only FDA-approved therapy for this autoimmune skin disorder.<\/p>\n<p>The post <a href=\"https:\/\/medcitynews.com\/2026\/10\/pfizer-vitiligo-litfulo-ritlecitinib-jak-tec-inhibitor-autoimmune-disease-immunology-pfe\/\">Pfizer Pill\u2019s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions<\/a> appeared first on <a href=\"https:\/\/medcitynews.com\">MedCity News<\/a>.<\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>Pfizer\u2019s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during European Academy of Dermatology and Venereology annual meeting. If Pfizer\u2019s daily pill is approved, it would compete against an Incyte topical cream that is currently the only FDA-approved therapy for this autoimmune skin disorder. The post Pfizer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7073312,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[110368,97673,97677,97679,234072,100628,234073,234074,223622,12380,234075],"tags":[11603,113462,19889,3404,29323,10484,9108,56209,234077],"dealstore":[],"offerexpiration":[],"class_list":["post-7073310","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-autoimmune-disease","category-biopharma","category-biopharma-nl","category-clinical-trials","category-immunology","category-inflammation","category-jak-inhibitor","category-litfulo","category-pfizer","category-pharma","category-vitiligo","tag-data","tag-ema","tag-fda","tag-pave","tag-pfizer","tag-phase","tag-pills","tag-submissions","tag-vitiligo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pfizer Pill\u2019s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions - Som2ny Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fivemor.com\/?p=7073310\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Pill\u2019s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions - Som2ny Network\" \/>\n<meta property=\"og:description\" content=\"Pfizer\u2019s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during European Academy of Dermatology and Venereology annual meeting. If Pfizer\u2019s daily pill is approved, it would compete against an Incyte topical cream that is currently the only FDA-approved therapy for this autoimmune skin disorder. The post Pfizer [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fivemor.com\/?p=7073310\" \/>\n<meta property=\"og:site_name\" content=\"Som2ny Network\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-02T20:13:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/10\/vitiligo_hands.jpg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/fivemor.com\/?p=7073310#article\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/?p=7073310\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\"},\"headline\":\"Pfizer Pill\u2019s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions\",\"datePublished\":\"2026-10-02T20:13:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=7073310\"},\"wordCount\":89,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=7073310#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/10\/vitiligo_hands.jpg\",\"keywords\":[\"Data\",\"EMA\",\"FDA\",\"Pav\u00e9\",\"Pfizer\",\"Phase\",\"Pills\",\"Submissions\",\"Vitiligo\"],\"articleSection\":[\"Autoimmune disease\",\"BioPharma\",\"biopharma nl\",\"Clinical Trials\",\"immunology\",\"inflammation\",\"JAK inhibitor\",\"Litfulo\",\"Pfizer\",\"Pharma\",\"vitiligo\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/fivemor.com\/?p=7073310#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fivemor.com\/?p=7073310\",\"url\":\"https:\/\/fivemor.com\/?p=7073310\",\"name\":\"Pfizer Pill\u2019s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions - Som2ny Network\",\"isPartOf\":{\"@id\":\"https:\/\/fivemor.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/fivemor.com\/?p=7073310#primaryimage\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/?p=7073310#primaryimage\"},\"thumbnailUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/10\/vitiligo_hands.jpg\",\"datePublished\":\"2026-10-02T20:13:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fivemor.com\/?p=7073310#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fivemor.com\/?p=7073310\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/?p=7073310#primaryimage\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/10\/vitiligo_hands.jpg\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/10\/vitiligo_hands.jpg\",\"width\":724,\"height\":483},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fivemor.com\/?p=7073310#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fivemor.com\/?bp_activities=1\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Pill\u2019s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fivemor.com\/#website\",\"url\":\"https:\/\/fivemor.com\/\",\"name\":\"Som2ny Network\",\"description\":\"Daily Deals\",\"publisher\":{\"@id\":\"https:\/\/fivemor.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fivemor.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fivemor.com\/#organization\",\"name\":\"Som2ny Network\",\"url\":\"https:\/\/fivemor.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"contentUrl\":\"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png\",\"width\":300,\"height\":86,\"caption\":\"Som2ny Network\"},\"image\":{\"@id\":\"https:\/\/fivemor.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fivemor.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/fivemor.com\"],\"url\":\"https:\/\/fivemor.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pfizer Pill\u2019s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions - Som2ny Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fivemor.com\/?p=7073310","og_locale":"en_US","og_type":"article","og_title":"Pfizer Pill\u2019s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions - Som2ny Network","og_description":"Pfizer\u2019s Litfulo significantly improved skin pigment measures in two pivotal studies in vitiligo, results that were presented during European Academy of Dermatology and Venereology annual meeting. If Pfizer\u2019s daily pill is approved, it would compete against an Incyte topical cream that is currently the only FDA-approved therapy for this autoimmune skin disorder. The post Pfizer [&hellip;]","og_url":"https:\/\/fivemor.com\/?p=7073310","og_site_name":"Som2ny Network","article_published_time":"2026-10-02T20:13:21+00:00","og_image":[{"url":"https:\/\/medcitynews.com\/wp-content\/uploads\/sites\/7\/2026\/10\/vitiligo_hands.jpg","type":"","width":"","height":""}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fivemor.com\/?p=7073310#article","isPartOf":{"@id":"https:\/\/fivemor.com\/?p=7073310"},"author":{"name":"admin","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371"},"headline":"Pfizer Pill\u2019s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions","datePublished":"2026-10-02T20:13:21+00:00","mainEntityOfPage":{"@id":"https:\/\/fivemor.com\/?p=7073310"},"wordCount":89,"commentCount":0,"publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"image":{"@id":"https:\/\/fivemor.com\/?p=7073310#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/10\/vitiligo_hands.jpg","keywords":["Data","EMA","FDA","Pav\u00e9","Pfizer","Phase","Pills","Submissions","Vitiligo"],"articleSection":["Autoimmune disease","BioPharma","biopharma nl","Clinical Trials","immunology","inflammation","JAK inhibitor","Litfulo","Pfizer","Pharma","vitiligo"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fivemor.com\/?p=7073310#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fivemor.com\/?p=7073310","url":"https:\/\/fivemor.com\/?p=7073310","name":"Pfizer Pill\u2019s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions - Som2ny Network","isPartOf":{"@id":"https:\/\/fivemor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fivemor.com\/?p=7073310#primaryimage"},"image":{"@id":"https:\/\/fivemor.com\/?p=7073310#primaryimage"},"thumbnailUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/10\/vitiligo_hands.jpg","datePublished":"2026-10-02T20:13:21+00:00","breadcrumb":{"@id":"https:\/\/fivemor.com\/?p=7073310#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fivemor.com\/?p=7073310"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/?p=7073310#primaryimage","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/10\/vitiligo_hands.jpg","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/10\/vitiligo_hands.jpg","width":724,"height":483},{"@type":"BreadcrumbList","@id":"https:\/\/fivemor.com\/?p=7073310#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fivemor.com\/?bp_activities=1"},{"@type":"ListItem","position":2,"name":"Pfizer Pill\u2019s Phase 3 Data in Vitiligo Pave Way for FDA, EMA Submissions"}]},{"@type":"WebSite","@id":"https:\/\/fivemor.com\/#website","url":"https:\/\/fivemor.com\/","name":"Som2ny Network","description":"Daily Deals","publisher":{"@id":"https:\/\/fivemor.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fivemor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fivemor.com\/#organization","name":"Som2ny Network","url":"https:\/\/fivemor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/","url":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","contentUrl":"https:\/\/fivemor.com\/wp-content\/uploads\/2026\/07\/4a0953c4-logo-300x86-1.png","width":300,"height":86,"caption":"Som2ny Network"},"image":{"@id":"https:\/\/fivemor.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/fivemor.com\/#\/schema\/person\/b85e3c3dc0e1daea076524dc8810c371","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fivemor.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/729ae85bf62b9917e93538db2f2688ca?s=96&r=g&default=https%3A%2F%2Ffivemor.com%2Fwp-content%2Fplugins%2Fbuddypress-first-letter-avatar%2Fimages%2Fdefault%2F96%2Flatin_a.png","caption":"admin"},"sameAs":["https:\/\/fivemor.com"],"url":"https:\/\/fivemor.com\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/7073310","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7073310"}],"version-history":[{"count":0,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/posts\/7073310\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=\/wp\/v2\/media\/7073312"}],"wp:attachment":[{"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7073310"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7073310"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7073310"},{"taxonomy":"dealstore","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fdealstore&post=7073310"},{"taxonomy":"offerexpiration","embeddable":true,"href":"https:\/\/fivemor.com\/index.php?rest_route=%2Fwp%2Fv2%2Fofferexpiration&post=7073310"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}